A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study

Journal of Pain and Symptom Management

Volumn 39, Issue 5, 2010, Pages 839-846

  von Gruenigen, Vivian E ^a   Huang, Helen Q ^b   Gil, Karen M ^c,d   Gibbons, Heidi E ^a   Monk, Bradley J ^e   Rose, Peter G ^f   Armstrong, Deborah K ^g   Cella, David ^h,i   Wenzel, Lari ^e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c AKRON GENERAL MEDICAL CENTER   (United States)

^d NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Center for Outcomes Research and Education   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

chemotherapy; Ovarian cancer; quality of life

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; EMOTION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHYSICAL CAPACITY; QUALITY OF LIFE; SCORING SYSTEM; SOCIAL SUPPORT; TREATMENT OUTCOME; WELLBEING;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; FEMALE; HEALTH STATUS; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRES; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 77952100387     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.09.022     Document Type: Article

References (21)

1. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 11 (1993) 570-579
2. Webster K., Cella D., and Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1 (2003) 79
3. Brucker P.S., Yost K., Cashy J., Webster K., and Cella D. General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G). Eval Health Prof 28 (2005) 192-211
4. Holzner B., Kemmler G., Cella D., et al. Normative data for function assessment of cancer therapy-general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 43 (2004) 153-160
5. Donaldson G.W., and Moinpour C.M. Individual differences in quality-of-life treatment response. Med Care 40 (2002) 39-53
6. Gil K.M., Gibbons H.E., Jenison E.L., Hopkins M.P., and von Gruenigen V.E. Baseline characteristics influencing quality of life in women undergoing gynecologic oncology surgery. Health Qual Life Outcomes 5 (2007) 25
7. Wenzel L., Vergote I., and Cella D. Quality of life in patients receiving treatment for gynecologic malignancies: special considerations for patient care. Int J Gynaecol Obstet 83 Suppl 1 (2003) 211-229
8. von Gruenigen V.E., Gil K.M., Huang H., et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer 115 (2009) 4857-4864
9. Wenzel L., Huang H.Q., Monk B.J., Rose P.G., and Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 23 (2005) 5605-5612
10. Wenzel L.B., Huang H.Q., Armstrong D.K., Walker J.L., Cella D., and Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 437-443
11. Armstrong D.K., Bundy B., Wenzel L., et al., Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 54 (2006) 34-43
12. Rose P.G., Nerenstone S., Brandy M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351 (2004) 2489-2497
13. Basen-Engquist K., Bodurka-Bevers D., Fitzgerald M.A., et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol 19 (2001) 1809-1817
14. Fairclough D.L., and Cella D.F. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res 5 (1996) 321-329
15. Cella D., Hahn E., and Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11 (2002) 207-221
16. Yost K.J., and Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences. Eval Health Prof 28 (2005) 172-191
17. Vickers A.J. Statistical considerations for use of composite health-related quality-of-life scores in randomized trials. Qual Life Res 13 (2004) 717-723
18. Wan G.J., Counte M.A., Cella D.F., et al. An analysis of the impact of demographic, clinical, and social factors on health-related quality of life. Value Health 2 (1999) 308-318
19. Movsas B., Scott C., and Watkins-Bruner D. Pretreatment factors significantly influence qualify of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. Int J Radiat Oncol Biol Phys 65 (2006) 830-835
20. Coughlin S.S. Surviving cancer or other serious illness: a review of individual and community resources. CA Cancer J Clin 58 (2008) 60-64
21. Wenzel L.B., Donnelly J.P., Fowler J., et al. Resilience, reflection and residual stress in ovarian cancer survivorship: a Gynecologic Oncology Group study. Psychooncology 11 (2002) 142-153